title: A pilot study on lidocaine tape therapy for convulsions with mild gastroenteritis.
abstract: The aim of this study was to clarify the efficacy and safety of lidocaine tape therapy (LDT) in patients with convulsions with mild gastroenteritis (CwG). Twenty-one consecutive episodes of CwG were treated with LDT therapy. The dose of LDT was 36 mg in patients with body weights of <15 kg, 54 mg in those with body weights between 15 and 20 kg, and 72 mg in those with body weights of >20 kg. LDT was attached on the back of each patient every 12 h. Application of LDT was continued for 48 h. The serum levels of lidocaine (LD) were measured 4 h after the first attachment of LDT. The seizures completely ceased in 13 episodes (62%) after the application of LDT, while a recurrence of seizures was observed in the other 8 episodes. Drip infusion of LD was performed in 4 of these 8 episodes. The serum LD levels were only measurable in 6 infants (average, 0.4 microg/ml; range, 0.2-0.5 microg/ml). In the other patients, the serum LD levels were below the lower limit of measurement. Adverse effects of LDT were not observed in any patients. LDT therapy was safe and effective in patients with CwG.
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan. okumura@med.nagoya-u.ac.jp
authors.forename: Akihisa
authors.initials: A
authors.lastname: Okumura
authors.forename: Takuya
authors.initials: T
authors.lastname: Tanabe
authors.forename: Toru
authors.initials: T
authors.lastname: Kato
authors.forename: Fumio
authors.initials: F
authors.lastname: Hayakawa
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000279:Administration, Cutaneous; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005759:Gastroenteritis / Q000150:complications*; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008012:Lidocaine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008297:Male; D010865:Pilot Projects; D012008:Recurrence; D012640:Seizures / Q000209:etiology* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000927:Anticonvulsants; D008012:Lidocaine